Pharmaceuticals, Biotechnology & Life Sciences

Johnson & Johnson’s two‑year ICOTYDE data show sustained plaque psoriasis clearance, strong safety and investor optimism, signaling a promising future for the biologic.

Cronos Group Inc. gears up for its Q3 2026 earnings, highlighting cannabis brand growth, tokenomics impact, and investor guidance—don’t miss the webcast.

LB Pharmaceuticals’ Phase‑III trial of LB‑102 aims to transform schizophrenia care by tackling unmet negative and cognitive symptoms, offering hope for next‑generation treatment.

Discover how Eloxx Pharmaceuticals is pioneering RNA therapies for rare genetic diseases, navigating market volatility while aiming for breakthrough treatments.

Explore Greenwich Lifesciences’ journey: a Texas‑based biopharma pushing cancer therapies amid market volatility and strong investor optimism.

Trulieve Cannabis Corp. pays off a $65 million Florida mortgage, cutting debt and boosting cash flow to fuel expansion into new states like Georgia and Texas.

Explore InflaRx NV—Germany’s leading monoclonal‑antibody biopharma—its market comeback, robust pipeline for inflammatory diseases, and investor outlook.

Halozyme wins Dutch court ruling against Merck’s Keytruda SC, blocking sales in key EU markets and boosting its ENHANZE drug‑delivery patent.

Merck’s European Keytruda injectable launch halted by Dutch patent ruling—learn how this setback may reshape its oncology strategy and investor outlook.

Gerresheimer AG’s latest voting‑rights disclosure hints at a possible takeover, amid booming drug‑delivery markets and growing investor interest.